Pharmacovigilance is a high‑stakes function, where leadership gaps, regulatory pressure, and operational disruption can quickly translate into patient risk, inspection findings, and enterprise value erosion. As regulatory expectations intensify and pharma companies face inspections, product launches, M&A activity, and leadership transitions, interim pharmacovigilance leaders are most often engaged at moments of elevated risk. They bring immediate authority, inspection‑tested judgment, and the ability to stabilize safety organizations when oversight, decision‑making, and regulatory confidence matter most.
For a deeper look at how interim leaders accelerate performance across the pharmacovigilance lifecycle, download our booklet, “5 Ways Interim Leaders Accelerate Performance in Pharmacovigilance.”
